Vir Biotechnology, Inc. — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-03-01

Reporting Person: Sigal Charles Elliott (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-01	Common Stock	P	2500	$22.7262	Acquired	10000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9779	Direct

Footnotes

F1: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.595 to $22.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.